Raleigh Capital Management Inc. Purchases 5,864 Shares of Sanofi (NASDAQ:SNY)

Raleigh Capital Management Inc. boosted its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 18.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,299 shares of the company's stock after purchasing an additional 5,864 shares during the period. Sanofi accounts for approximately 1.0% of Raleigh Capital Management Inc.'s portfolio, making the stock its 21st biggest position. Raleigh Capital Management Inc.'s holdings in Sanofi were worth $2,124,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of SNY. Price T Rowe Associates Inc. MD boosted its position in Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Boston Partners boosted its position in Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC boosted its position in Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after purchasing an additional 1,705,148 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Sanofi by 969.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock valued at $45,850,000 after purchasing an additional 861,770 shares during the last quarter. Finally, Regal Partners Ltd acquired a new stake in Sanofi during the fourth quarter valued at $35,034,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of Sanofi stock traded up $0.34 during trading on Tuesday, reaching $48.66. The company's stock had a trading volume of 339,728 shares, compared to its average volume of 2,330,580. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The business's fifty day moving average price is $50.52 and its 200-day moving average price is $52.12. The firm has a market cap of $119.33 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 1.05 and a beta of 0.48. Sanofi has a one year low of $45.80 and a one year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period in the previous year, the company posted $1.78 earnings per share. The company's quarterly revenue was down 11.0% compared to the same quarter last year. As a group, equities research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were paid a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. Sanofi's payout ratio is currently 57.14%.

Analysts Set New Price Targets

A number of brokerages have weighed in on SNY. Morgan Stanley set a $56.00 price target on Sanofi in a research report on Monday, June 2nd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, The Goldman Sachs Group initiated coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target for the company. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of "Buy" and a consensus target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.